-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
Phase
Interventional
-
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
A study called TNG462-C101 is being conducted to test a new medicine called TNG462 on patients with advanced or metastatic solid tumors who have a ...
Phase
Interventional
